Erythropoietin Therapy in Critically Ill and Acute Kidney Injury Patients

Abstract In critically ill patients, the use of recombinant human erythropoietin, rHuEPO, and other erythropoiesis-stimulating agents (ESAs) has been advocated for the management of anemia and for tissue protection. Early enthusiasm has been tempered by the overall lack of positive outcomes except in selected groups. Here we review the use of ESAs in both treatment areas.

• Publication year

  2019

• Venue

  Critical Care Nephrology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-323-44942-7.00224-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoiesis stimulating agents and reno-protection: a meta-analysis

  2017cited by this paper
• Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients: A Systematic Review and Meta-analysis

  2017cited by this paper
• Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

  2016cited by this paper
• Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest: A Multicenter, Randomized Controlled Trial.

  2016cited by this paper
• Effect of a Single Bolus of Erythropoietin on Renoprotection in Patients Undergoing Thoracic Aortic Surgery With Moderate Hypothermic Circulatory Arrest.

  2016cited by this paper
• The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.

  2016cited by this paper
• Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2015cited by this paper
• Bridging Translation by Improving Preclinical Study Design in AKI.

  2015cited by this paper
• Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.

  2015cited by this paper
• Progressive hemorrhagic injury after severe traumatic brain injury: effect of hemoglobin transfusion thresholds.

  2015cited by this paper
• A systematic review of pre‐operative anaemia and blood transfusion in patients with fractured hips

  2015cited by this paper
• Erythropoietin administration for prevention of cardiac surgery-associated acute kidney injury: a meta-analysis of randomized controlled trials.

  2015cited by this paper
• Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review.

  2015cited by this paper
• Erythropoietin and Protection of Renal Function in Cardiac Surgery (the EPRICS Trial)

  2014cited by this paper
• CONFIRMATION OF KEY TREAT FINDINGS IN RED-HF, A PLACEBO CONTROLLED HEART FAILURE TRIAL

  2014cited by this paper
• Human Choriogonadotropin and Epoetin Alfa in Acute Ischemic Stroke Patients (REGENESIS-LED Trial)

  2014cited by this paper
• Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial.

  2014cited by this paper
• Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study

  2014cited by this paper
• Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data.

  2014cited by this paper
• Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

  2013cited by this paper
• Impact of Erythropoietin on Intensive Care Unit Patients

  2013cited by this paper
• Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

  2013cited by this paper
• The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials.

  2013cited by this paper
• Treatment of anemia with darbepoetin alfa in systolic heart failure.

  2013cited by this paper
• Progress in detecting cell-surface protein receptors: the erythropoietin receptor example

  2013cited by this paper
• Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial

  2013cited by this paper
• Neuroprotective Effects of Erythropoietin in Patients with Carbon Monoxide Poisoning

  2013cited by this paper
• Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety

  2013cited by this paper
• Intra-operative erythropoietin during laparoscopic partial nephrectomy is not renoprotective

  2012cited by this paper
• Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement.

  2012cited by this paper
• A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study.

  2012cited by this paper
• Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron

  2012cited by this paper
• Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study.

  2012cited by this paper
• Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.

  2012cited by this paper
• Anemia in critical illness: insights into etiology, consequences, and management.

  2012cited by this paper
• Red blood cell transfusion compared with gelatin solution and no infusion after cardiac surgery: effect on microvascular perfusion, vascular density, hemoglobin, and oxygen saturation

  2012cited by this paper
• Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double‐blind placebo‐controlled pilot study

  2012cited by this paper
• Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

  2012cited by this paper
• Erythropoietin Improves Long-Term Outcomes in Patients with Acute Kidney Injury after Coronary Artery Bypass Grafting

  2012cited by this paper
• The effect of erythropoietin on normal and neoplastic cells

  2012cited by this paper
• Lack of expression and function of erythropoietin receptors in the kidney.

  2012cited by this paper
• Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study

  2012cited by this paper
• Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

  2012cited by this paper
• Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

  2011cited by this paper
• Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

  2011cited by this paper
• Effect of Single Recombinant Human Erythropoietin Injection on Transfusion Requirements in Preoperatively Anemic Patients Undergoing Valvular Heart Surgery

  2011cited by this paper
• Liberal or restrictive transfusion in high-risk patients after hip surgery.

  2011cited by this paper
• Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke

  2011cited by this paper
• The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention.

  2011cited by this paper
• Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials.

  2011cited by this paper
• Hepcidin and disorders of iron metabolism.

  2011cited by this paper
• Outcomes with the Use of Recombinant Human Erythropoietin in Critically Ill Burn Patients

  2010cited by this paper
• Erythropoiesis Stimulating Agent Administration Improves Survival After Severe Traumatic Brain Injury: A Matched Case Control Study

  2010cited by this paper
• Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomized, Double-Blind Trial

  2010cited by this paper
• Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).

  2010cited by this paper
• Treatment of anemia with darbepoetin alfa in heart failure.

  2010cited by this paper
• Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

  2010cited by this paper
• Impact of erythropoiesis‐stimulating agents on morbidity and mortality in patients with heart failure: an updated, post‐TREAT meta‐analysis

  2010cited by this paper
• Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease

  2010cited by this paper
• Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study.

  2009cited by this paper
• Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

  2009cited by this paper
• Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.

  2009cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article.

  2009cited by this paper
• Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction.

  2009cited by this paper
• Epidemiology and 12-month outcomes from traumatic brain injury in australia and new zealand.

  2008cited by this paper
• Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

  2008cited by this paper
• Neuroprotection with Erythropoietin Administration Following Controlled Cortical Impact Injury in Rats

  2007cited by this paper
• Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study.

  2007cited by this paper
• Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials

  2007cited by this paper
• Efficacy and safety of epoetin alfa in critically ill patients.

  2007cited by this paper
• Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial

  2007cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• Does the Use of Erythropoietin Reduce the Risk of Exposure to Allogeneic Blood Transfusion in Cardiac Surgery? A Systematic Review and Meta‐Analysis

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Anaemia during critical illness.

  2006cited by this paper
• Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: A randomized, double-blind, placebo-controlled trial*

  2006cited by this paper
• Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.

  2006cited by this paper
• Evaluation of blood transfusion effects on mixed venous oxygen saturation and lactate levels in patients with SIRS/sepsis.

  2005cited by this paper
• Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]

  2005cited by this paper
• Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.

  2005cited by this paper
• Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST)

  2005cited by this paper
• Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial.

  2004cited by this paper
• Erythropoietin protects against ischaemic acute renal injury.

  2004cited by this paper
• Anemia and blood transfusion in the critically ill patient: role of erythropoietin

  2004cited by this paper
• Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

  2003cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Anemia and blood transfusion in critically ill patients.

  2002cited by this paper
• Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.

  2002cited by this paper
• Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

  2001cited by this paper
• Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial*

  2001cited by this paper
• Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness.

  2001cited by this paper
• A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

  1999cited by this paper
• A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients.

  1995cited by this paper

• No citing papers are available for this paper.